Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Stakeholder Insight: HIV Therapy Dynamics' returned 6 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity   Datamonitor, May 2010, Pages: 108 Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity Dealmaking and Industry Outlook: Antivirals   Decision Resources, Inc., March 2010, Pages: 35 ’s MAb-Based Therapies Two Gilead Sciences’ Deals A New HIV Strategy for Roche in Emerging Markets Roche’s MAb-Based Infl uenza Therapies SIGA Develops Defenses Against Biological Warfare Vertex Getting Maximum Benefit from Combination Products   Decision Resources, Inc., May 2007, Pages: 40 product development. - Expert Commentaries: Insights from Decision Resources analysts, consultants, and directors. Executive Summary Strategic Considerations Stakeholder Implications The Breadth Biopharma Quarter: Key Trends and Events of the Third Quarter of 2009   Decision Resources, Inc., Dec 2009, Pages: 37 , was controversial. How has that vaccine been received? What events have occurred since that initial approval? How are commercial dynamics related to this marketplace evolving? Scope - Events: Genetic testing Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life   Datamonitor, March 2009, Pages: 122 Course (DOTS) programme 85 Payment for drugs and services 86 Treatment for HIV infected patients 86 Antiretroviral therapy 86 Drug-drug interactions and toxicity 87 Immune reconstitution inflammatory How to Get Ahead with Pharmacogenomics   Decision Resources, Inc., March 2008, Pages: 42 is a reasonable action plan to follow, and why is educating stakeholders so very important? Scope - Industry experts: Twelve interviews and/or commentaries from industry leaders who share their insights Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network